The article reviews the novel antibody-drug conjugate (ADC) Datopotamab deruxtecan (Dato-DXd) for the treatment of triple-negative breast cancer (TNBC). TNBC is a highly aggressive subtype with limited treatment options, and ADCs have shown promising results in breast cancer therapy. Dato-DXd, directed against the TROP-2 receptor, has demonstrated encouraging efficacy and safety in early clinical trials. The mechanism of action involves the delivery of a cytotoxic agent to tumor cells, with a high drug-to-antibody ratio (DAR) and a stable linker. Dato-DXd induces DNA damage and apoptosis, leading to cellular death. Early clinical trials, such as TROPION-PanTumor01 and BEGONIA, have reported promising results, with high overall response rates and manageable safety profiles. Ongoing phase III trials, including TROPION-Breast01, TROPION-Breast02, and TROPION-Breast03, are evaluating Dato-DXd in combination with other therapies, particularly in the neoadjuvant setting. The article concludes by highlighting the potential of Dato-DXd in improving the treatment landscape for TNBC, despite the ongoing challenges in accessing these advanced therapies.The article reviews the novel antibody-drug conjugate (ADC) Datopotamab deruxtecan (Dato-DXd) for the treatment of triple-negative breast cancer (TNBC). TNBC is a highly aggressive subtype with limited treatment options, and ADCs have shown promising results in breast cancer therapy. Dato-DXd, directed against the TROP-2 receptor, has demonstrated encouraging efficacy and safety in early clinical trials. The mechanism of action involves the delivery of a cytotoxic agent to tumor cells, with a high drug-to-antibody ratio (DAR) and a stable linker. Dato-DXd induces DNA damage and apoptosis, leading to cellular death. Early clinical trials, such as TROPION-PanTumor01 and BEGONIA, have reported promising results, with high overall response rates and manageable safety profiles. Ongoing phase III trials, including TROPION-Breast01, TROPION-Breast02, and TROPION-Breast03, are evaluating Dato-DXd in combination with other therapies, particularly in the neoadjuvant setting. The article concludes by highlighting the potential of Dato-DXd in improving the treatment landscape for TNBC, despite the ongoing challenges in accessing these advanced therapies.